Neurodevelopmental outcomes of preterm infants fed high-dose docosahexaenoic acid: A randomized controlled trial

Makrides, Maria, Gibson, Robert A., McPhee, Andrew J., Collins, Carmel T., Davis, Peter G., Doyle, Lex W., Simmer, Karen, Colditz, Paul B., Morris, Scott, Smithers, Lisa G., Willson, Kristyn and Ryan, Philip (2009) Neurodevelopmental outcomes of preterm infants fed high-dose docosahexaenoic acid: A randomized controlled trial. Obstetrical and Gynecological Survey, 64 5: 297-298. doi:10.1097/01.ogx.0000347341.63370.57


Author Makrides, Maria
Gibson, Robert A.
McPhee, Andrew J.
Collins, Carmel T.
Davis, Peter G.
Doyle, Lex W.
Simmer, Karen
Colditz, Paul B.
Morris, Scott
Smithers, Lisa G.
Willson, Kristyn
Ryan, Philip
Title Neurodevelopmental outcomes of preterm infants fed high-dose docosahexaenoic acid: A randomized controlled trial
Journal name Obstetrical and Gynecological Survey   Check publisher's open access policy
ISSN 0029-7828
1533-9866
Publication date 2009-05-01
Year available 2009
Sub-type Editorial
DOI 10.1097/01.ogx.0000347341.63370.57
Open Access Status
Volume 64
Issue 5
Start page 297
End page 298
Total pages 3
Place of publication Philadelphia, PA, United States
Publisher Lippincott Williams & Wilkins
Language eng
Subject 111403 Paediatrics
920501 Child Health
Abstract Infants born before 33 weeks’ gestation are at high risk of developmental disorders and learning disabilities. An inadequate endogenous supply of docosahexaenoic acid (DHA), a major brain lipid, may contribute to this poor developmental outcome. Trials evaluating the possible benefit of dietary DHA on the neurodevelopment of preterm infants have been inconclusive. This randomized, double-blind, controlled trial was designed to evaluate the long-term efficacy of a high-dose DHA enteral feed on the neurodevelopment of preterm infants born at less than 33 weeks’ gestation. A total of 657 infants were randomized to receive an enteral feed containing 1% total fatty acids (high-DHA group, n = 322) or a standard feed containing 0.3% total fatty acids (standard-DHA group, n = 335) from day 2 to 4 of life until term corrected age. The data were stratified by birth weight (<1250 vs. >1250 g) and infant gender. At 18 months follow-up, neurodevelopment was assessed using the Bayley Mental Development Index (MDI). In the whole study group, no difference was found in the unadjusted MDI scores of the children receiving high versus standard DHA feeds (mean difference: 1.9, 95% CI:-1.0–4.7), or among boys in the high versus standard feed groups. Adjustment for confounding variables did not change these results. However, girls receiving high-DHA feeds had significantly higher MDI scores than those receiving standard-DHA feeds (unadjusted mean difference: 4.7; 95% CI: 0.5–8.8, P = 0.03; adjusted mean difference: 4.5; 95% CI: 0.5–8.5, P = 0.03). Although ingestion of a high-DHA dose does not increase the MDI scores of all preterm infants born before 33 weeks, it was associated with an increase of MDI scores among girls. These data suggest that future trials with higher doses should be considered.
Keyword Preterm infants
Neurodevelopmental outcome
Neonatal
Docosahexaenoic Acid
Controlled Trial
Q-Index Code CX
Q-Index Status Confirmed Code
Institutional Status UQ

 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 2 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 03 Sep 2009, 18:12:49 EST by Mr Andrew Martlew on behalf of UQ Centre for Clinical Research